Most of the current disease-modifying therapies available for the treatment of multiple sclerosis (MS) are administered by injection. This is a source of fear for many patients and a substantial cause of non-adherence to treatment. Autoinjectors can address this by ensuring that the injection is made at the correct depth and can markedly improve the comfort and tolerability of administration compared with manual syringes.
of MS. For example, in the Prevention of Relapses and Disability by
Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) trial, 61.9% patients receiving INFβ-1a 44µg three-times weekly were reported to have experienced ISRs compared with 21.9% of patients receiving placebo. A similar proportion of patients experienced ISRs in the initial phase III INFβ-1b trial, where 69% of patients receiving INFβ-1b 250µg every other day experienced ISRs compared with only 6% of patients receiving placebo. 13 However, in the Betaferon in Newly
Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) trial, in which the majority of patients used autoinjectors, the incidence of reported ISRs was lower than the initial phase III trial; 48.3% for
INFβ-1b compared with 8.5% for placebo, 14, 15 suggesting that the use of autoinjectors may decrease the incidence of ISRs.
Despite the high incidence of ISRs reported in clinical trials, it is important to note that the incidence of these decreases over time 10, 13, 14 making the patient's experience during the first few weeks of a new injectable treatment an important factor in long term adherence. 12, 16 Injection procedure discomfort also affects treatment adherence. In one observational study, up to 51% of 798 patients who responded to an Internet survey, admitted non-adherence to their DMT regimenmissing any injection within the last four weeks. 17 In this study, many patients reported that the principal reasons for missing an injection were associated with the injection procedure itself, such as being tired of receiving injections (16%), skin reactions (5%), pain at injection sites (7%), not feeling like administering injections (22%) and injection-related anxiety (3%). Four per cent of patients also reported that non-adherence developed because of an absence of someone to help administer the injection. The authors also noted that as DMTs have different dosing regimens, the consequences of missed injections would not necessarily be the same for different therapies.
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The data from clinical trials regarding the incidence of ISRs and the reported lack of adherence from this observational study highlights the need for improved delivery devices to ameliorate patient discomfort during the injection procedure, to improve patient compliance and to reduce the number of ISRs.
Improving Interferon Beta Autoinjectors Used to Treat Multiple Sclerosis
Although some of the adverse effects of injections cannot be altered, manufacturers can improve upon a few aspects of the injection procedure, and attempt to reduce the burden of the injection process. 18 Autoinjectors have been shown to improve both the tolerability and adherence of injections. 9 In addition, pain experienced by patients during the injection procedure is associated with needle gauge:
the smaller the outer diameter of the needle, the less pain is experienced, 19, 20 and indeed, some studies suggest that patients experience less fear of the injection when using a smaller needle. 21 The components of the formulation may also influence injection-site reactions and patient-reported pain. For the injection of some medications, such as lidocaine, a pH-buffered formulation has been shown to be particularly important and may have a greater overall effect on pain than needle size. 22 However, since many of the interferon medications are available as pre-filled syringes the formulations are most likely optimised to prevent destabilisation of the interferon preparation during storage rather than to ensure a less painful injection.
Subcutaneous INFβ-1a may cause occasional injection site burning possibly secondary to the acidic pH of the solution but it is unclear whether this leads to an increased incidence of ISRs.
10,23
The overall treatment satisfaction of patients is subjective and it is difficult to measure in an objective way their perception of how 
Benefits of Using an Autoinjector
In an attempt to improve therapy adherence, it is important to consider ways that improve the patient experience of administering an injectable DMT and using an autoinjector may help by overcoming possible hesitation and apprehension experienced when patients inject themselves. An autoinjector uses a spring-loaded syringe that automatically inserts the needle and administers a single-dose of the drug at the touch of a button.
Autoinjectors have been shown to improve a number of injection-related adverse effects, including a reduction in the incidence of ISRs, and pain and trauma compared with manual injections. [24] [25] [26] Autoinjectors make the injection process easier and are generally preferable to conventional procedures for patients who have poor manual dexterity or a tremor, allowing individuals to self-inject rather than relying on a relative or carer to administer the injection on their behalf. 18, 25 Injection devices usually hide the needle from view and may reduce anxiety in cases of needle phobia. In addition, the use of an autoinjector encourages the use of injection sites that would otherwise be difficult to reach using a manual injection, allowing more sites to be used, which in turn may prevent the overuse of more easily reached areas. As the autoinjector delivers the drug at a constant rate, the overall procedure may be more comfortable and with lower injection-site pain. Overall, compliance may be higher using autoinjectors compared with manual injection. 27 In addition, the sharpness of the needle (bevel) is also important; blunt needles are more painful when penetrating the skin, therefore, the sharper the better. Autoinjectors protect the needle from accidental knocks, thus maintaining both its sterility and sharpness. Lastly, autoinjectors need to be able to signal the end of the injection procedure, allowing the patient to pull the device safely away from the skin once the needle has retracted. The capability of recording the time and date of each dose may assist in the measurement of treatment compliance.
Clinical Data Supports the Use of Autoinjectors
In the observational cohort Betaferon versus Rebif Investigating
Higher Tolerability (BRIGHT) study the incidence of ISP and ISRs were assessed after the administration of either one of the two high-frequency, subcutaneously injected interferon-βs: INFβ-1b Multiple Sclerosis
using the Betaject reported that they were pain-free at all three time points compared with those using the Rebiject (see Figure 1 ). These results indicate that INFβ-1b is less painful to inject than INFβ-1a. The study also looked at the effect of needle size on the proportion of pain-free injections: patients who were using INFβ-1b reported more pain-free injections when using a smaller gauge needle - (29-30 rather than 25-27 gauge; see Figure 2 ). Furthermore, fewer patients using INFβ-1b were reported to have ISRs compared with those using
INFβ-1a. After the 15 consecutive injections assessed for the study, 51.8% of the INFβ-1b group versus 33.8% of the INFβ-1a group were reported to have no ISRs (p<0.0001; see Figure 3 ). Other AEs occurred at similar rates for both types of INFβ.
Another randomised trial compared the occurrence of ISRs in patients with relapsing-remitting MS (RRMS) who were using manual injection or an autoinjector to administer INFβ-1a. The incidence of ISRs was also reduced using an autoinjector compared with a manual injection.
In this open-label trial, fewer patients experienced ISRs diagnosed by a physician when using an autoinjector (78.7 versus 85.4%; p<0.001). 24 Furthermore, for patient-reported ISRs, a smaller proportion of patients using an autoinjector reported ISRs compared with those using manual injections (66.1 versus 71.8%, p<0.001).
In MS treatment, most autoinjectors and studies evaluating them involve SC injection. An exception to this is an ongoing phase III study that is evaluating a single-use pre-filled autoinjector for intramuscular (IM) injection of INFβ-1a. 28 This is an open-label, single-group study i.e. bevel five scored slightly better than bevel three for both 27-and 29-gauge needles. In addition, needles fitted with a rubber shield were perceived to cause less ISP than the needles with a thermoplastic elastomer shield. Nurses also reported that skin penetration was also improved by 69% with the 29-gauge/five-bevel needle compared with the 27-gauge/three-bevel needle. However, it is important to note that these healthy subjects were just pricked with the various needle sizes and did not receive any injected fluid. The collation of results from the 
Requirements of an Autoinjector and its Application Tool Kit
As with all device development, improvements to design and functionality are made by suggestions from advisory boards and market research specifically addressing the needs of patients, nurses and physicians. It is also important to get detailed input from specialist MS nurses as they are the healthcare professionals who train patients on how to self-inject and operate autoinjectors. As with all self-injected drugs, the patient needs an application tool kit, which includes everything needed to self-administer the drug: needles, vial adapters, alcohol swabs, needle disposal box and instructions for use. This kit needs to be simple and easy to use, ergonomic and most importantly, tested by patients with MS to ensure that it is possible to maintain sterile handling.
Currently, Extavia (INFβ-1b) is available in Europe as a lyophilised powder (300µg) for reconstitution in 1.2ml diluent (sodium chloride 0.54% solution) in a single-use glass syringe with a vial adapter and a separate 27-gauge needle. 29 The medication is then ready to be injected either manually or using an autoinjector. The current autoinjector and application tool kit have now been improved upon using feedback from specialist healthcare professional and patients using the injectable therapies. The EU application kit is more ergonomic for MS patients; it is now smaller, enables easier access to components and has an improved vial adaptor, enabling easier sterile handling.
Improving Autoinjectors -Advantages of the New ExtaviJect 30G
To endeavour to improve patient comfort during the administration of Compared with the Betaject Comfort, 71% said they would prefer to use the ExtaviJect 30G for injections to treat their multiple sclerosis, 67% believed the ExtaviJect 30G would be easier to load and 73% believed the ExtaviJect 30G would be easier to handle than the Betaject Comfort device (see Table 1 ). The patient interviews also investigated preferences of the ExtaviJect 30G compared with the previous device it replaces that has a 27-gauge needle. The preferred or 'useful', suggesting that although the device has a lot of features, they may not be appropriate for everyone. Furthermore, not all patients will want to use or understand how to use such a sophisticated high-technology device.
The decreased incidence of ISRs with autoinjectors compared with manual injection observed in clinical trials, and the ease of use of autoinjectors, suggests that patient adherence to therapy may be increased, and thus improve health outcomes for some patients. As with all autoinjectors, the Extavia delivery device, ExtaviJect 30G, will continue to evolve in line with feedback from patients, nurses and neurologists, and endeavour to boost patient comfort when delivering INFβ-1b. n
